Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Thursday

Tenaya Therapeutics (NASDAQ:TNYA) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Tenaya Therapeutics to post earnings of ($0.17) per share for the quarter.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06. On average, analysts expect Tenaya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $0.68 on Tuesday. The stock has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.66. The stock has a market cap of $111.02 million, a PE ratio of -0.71 and a beta of 3.01. Tenaya Therapeutics has a 1 year low of $0.36 and a 1 year high of $4.01.

Analyst Ratings Changes

Several brokerages recently issued reports on TNYA. Wall Street Zen raised Tenaya Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Chardan Capital reissued a “buy” rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a report on Thursday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Tenaya Therapeutics in a report on Friday, April 25th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Tenaya Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $6.25.

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors have recently made changes to their positions in the stock. Woodline Partners LP raised its holdings in shares of Tenaya Therapeutics by 30,563.2% in the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock worth $3,373,000 after acquiring an additional 5,896,873 shares during the last quarter. AQR Capital Management LLC acquired a new position in Tenaya Therapeutics in the first quarter valued at $442,000. Finally, Comerica Bank acquired a new position in Tenaya Therapeutics in the first quarter valued at $50,000. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.